Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer

Zhao,Bin; He,Tianlin

doi:10.3892/or.2014.3595

Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer

Authors:
- Bin Zhao
- Tianlin He
View Affiliations

Affiliations: Department of General Surgery, Shanghai Seventh People's Hospital, Shanghai 200137, P.R. China, Department of General Surgery, Changhai Hospital, Shanghai 200433, P.R. China
Published online on: November 10, 2014 https://doi.org/10.3892/or.2014.3595
Pages: 304-310

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chidamide is a newly designed histone deacetylase (HDAC) inhibitor that has been applied in clinical trials. This study aimed to test the effect of Chidamide on proliferation and apoptosis in pancreatic cancer cell lines and in vivo tumors, as well as to determine the underlying mechanism. The PaTu8988 pancreatic tumor cell line either in culture or inoculated in nude mice were used to evaluate the antitumor characteristics of Chidamide. Proliferation and apoptosis of cultured PaTu8988 cells were examined by CCK-8 assay and Annexin V-FITC/PI double staining assay, respectively. Alterations in protein expression, including Caspase-3, Bcl-2‑like protein 4 (Bax), B-cell lymphoma 2 (Bcl-2) and p21, were tested by western blot analysis. The mRNA of different HDACs was examined by quantitative polymerase chain reaction (qPCR) experiments. Chidamide suppressed cell proliferation and induced early apoptosis of pancreatic tumor cells in a dose‑dependent manner after 48 h of treatment. Similarly, the in vivo study using pancreatic tumor murine model showed that Chidamide administration significantly inhibited the growth of pancreatic tumor and induced tumor cell apoptosis. The in vitro and in vivo studies found that Chidamide treatment significantly decreased the expression of type I HDACs, uncleaved Caspase-3 and p21 and increased the ratio of Bax/Bcl-2 expression. The results from the in vitro and in vivo studies suggested Chidamide might suppress the proliferation of pancreatic tumor cells by downregulating the expression of type I HDACs and p21, and promoting mitochondrial apoptosis pathway-dependent cell apoptosis in a dose-dependent manner. The study provided more evidence for clinical administration of Chidamide that targets pancreatic tumor cells and identified potential molecular targets for the development of potent anticancer drugs.

View Figures

View References

1	Lennon AM, Wolfgang CL, Canto MI, et al: The early detection of pancreatic cancer: What will it take to diagnose and treat curable pancreatic neoplasia? Cancer Res. 74:3381–3389. 2014. View Article : Google Scholar : PubMed/NCBI
2	Vincent A, Herman J, Schulick R, Hruban RH and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011. View Article : Google Scholar : PubMed/NCBI
3	Zhu L, Yuan H, Guo C, et al: Zearalenone induces apoptosis and necrosis in porcine granulosa cells via a caspase-3- and caspase-9-dependent mitochondrial signaling pathway. J Cell Physiol. 227:1814–1820. 2012. View Article : Google Scholar
4	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
5	Shaib Y, Davila J and El-Serag H: The epidemiology of pancreatic cancer in the United States: changes below the surface. Aliment Pharmacol Ther. 24:87–94. 2006. View Article : Google Scholar : PubMed/NCBI
6	Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP and Ghaneh P: Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol. 25:2607–2615. 2007. View Article : Google Scholar : PubMed/NCBI
7	Burris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 15:2403–2413. 1997.PubMed/NCBI
8	Liu L, Chen B, Qin S, et al: A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells. Biochem Biophys Res Commun. 392:190–195. 2010. View Article : Google Scholar : PubMed/NCBI
9	Dong M, Ning ZQ, Xing PY, et al: Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas. Cancer Chemother Pharmacol. 69:1413–1422. 2012. View Article : Google Scholar : PubMed/NCBI
10	Zhou Y, Pan DS, Shan S, et al: Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in non-small-cell lung cancer cells. Biomed Pharmacother. 68:483–491. 2014. View Article : Google Scholar : PubMed/NCBI
11	Liu L, Chen B, Qin S, et al: A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells. Biochem Biophys Res Commun. 392:190–195. 2010. View Article : Google Scholar : PubMed/NCBI
12	Wang H, Guo Y, Fu M, et al: Antitumor activity of Chidamide in hepatocellular carcinoma cell lines. Mol Med Rep. 5:1503–1508. 2012.PubMed/NCBI
13	Ning ZQ, Li ZB, Newman MJ, et al: Chidamide(CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol. 69:901–909. 2012. View Article : Google Scholar
14	Gong K, Xie J, Yi H and Li W: CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells. Biochem J. 443:735–746. 2012. View Article : Google Scholar : PubMed/NCBI
15	Qiao Z, Ren S, Li W, et al: Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells. Biochem Biophys Res Commun. 434:95–101. 2013. View Article : Google Scholar : PubMed/NCBI
16	Qiao Z, Ren S, Li W, et al: Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells. Biochem Biophys Res Commun. 434:95–101. 2013. View Article : Google Scholar : PubMed/NCBI
17	Li D, Xie K, Wolff R and Abbruzzese JL: Pancreatic cancer. Lancet. 363:1049–1057. 2004. View Article : Google Scholar : PubMed/NCBI
18	Yen MC, Weng TY, Chen YL, et al: An HDAC inhibitor enhances cancer therapeutic efficiency of RNA polymerase III promoter-driven IDO shRNA. Cancer Gene Ther. 20:351–357. 2013. View Article : Google Scholar : PubMed/NCBI
19	Ning Z-Q, Li Z-B, Newman MJ, et al: Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol. 69:901–909. 2012. View Article : Google Scholar
20	Fiandalo MV and Kyprianou N: Caspase control: protagonists of cancer cell apoptosis. Exp Oncol. 34:165–175. 2012.PubMed/NCBI
21	Yang J, Liu X, Bhalla K, et al: Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science. 275:1129–1132. 1997. View Article : Google Scholar : PubMed/NCBI
22	Siu WP, Pun PB, Latchoumycandane C and Boelsterli UA: Bax-mediated mitochondrial outer membrane permeabilization (MOMP), distinct from the mitochondrial permeability transition, is a key mechanism in diclofenac-induced hepatocyte injury: Multiple protective roles of cyclosporin A. Toxicol Appl Pharmacol. 227:451–461. 2008. View Article : Google Scholar : PubMed/NCBI
23	Ohtsuka T, Buchsbaum D, Oliver P, Makhija S, Kimberly R and Zhou T: Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene. 22:2034–2044. 2003. View Article : Google Scholar : PubMed/NCBI
24	Elmore S: Apoptosis: a review of programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
25	Huang WJ, Liang YC, Chuang SE, et al: NBM-HD-1: A novel histone deacetylase inhibitor with anticancer activity. Evid Based Complement Alternat Med. 2012:7814172012. View Article : Google Scholar
26	Ohashi K, Nemoto T, Eishi Y, Matsuno A, Nakamura K and Hirokawa K: Expression of the cyclin dependent kinase inhibitor p21WAF1/CIP1 in oesophageal squamous cell carcinomas. Virchows Arch. 430:389–395. 1997. View Article : Google Scholar : PubMed/NCBI
27	Dai L, Liu Y, Liu J, et al: A novel cyclinE/cyclinA-CDK inhibitor targets p27^Kip1 degradation, cell cycle progression and cell survival: implications in cancer therapy. Cancer Lett. 333:103–112. 2013. View Article : Google Scholar : PubMed/NCBI
28	Hoefer J, Schäfer G, Klocker H, et al: PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21. Am J Pathol. 180:2097–2107. 2012. View Article : Google Scholar : PubMed/NCBI